RADNOR, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will be giving a presentation at the Jefferies Healthcare Conference in New York at 9:30 a.m. ET on Friday, June 9, 2023.
The live webcast of the presentation can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days.
2023 Jefferies Healthcare Conference:
| Date: | Friday, June 9, 2023 |
| Time: | 9:30 a.m. ET |
| Webcast Link |
About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is initially developing for the treatment of patients with uncontrolled or resistant hypertension. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.32 |
| Daily Change: | -0.29 -1.98 |
| Daily Volume: | 793,729 |
| Market Cap: | US$933.380M |
May 12, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
